Roundtable Discussion: Who Is the Amylin Patient, & What Will Make Clinicians Choose It?

2:30 pm - Thursday 3rd December 2026

  • Identify where amylin may offer a meaningful alternative for patients prioritizing tolerability, gradual weight loss, lower-BMI intervention or a different treatment experience
  • Examine its potential use after incretin intolerance, inadequate response, treatment plateau or discontinuation without assuming these groups are already clinically defined
  • Determine what evidence clinicians need to distinguish between amylin, incretins and combinations in individual patients
  • Develop practical scenarios for initiation, switching, sequencing, add-on treatment and maintenance